Financial Performance - The estimated net profit attributable to shareholders is expected to be a loss of between 74 million to 110.5 million RMB, compared to a loss of 130.87 million RMB in the same period last year [4]. - The estimated net profit after deducting non-recurring gains and losses is expected to be a loss of between 119 million to 178 million RMB, compared to a loss of 215.65 million RMB in the same period last year [4]. - The estimated operating revenue is projected to be between 2.26 billion to 2.61 billion RMB, an increase from 2.11 billion RMB in the same period last year [4]. Impairment Provisions - The company anticipates impairment provisions for fixed assets and inventory totaling approximately 6.8 million to 10.1 million RMB due to signs of impairment [7]. - The company expects to recognize goodwill impairment related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. in the range of approximately 11.6 million to 17.3 million RMB [7]. Non-Recurring Gains and Losses - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 4.5 million to 6.7 million RMB, mainly from investment income and government subsidies [7]. Financial Reporting - The financial data in the earnings forecast is based on preliminary estimates by the company's finance department and has not been audited by an accounting firm [8]. - The final financial data will be disclosed in the company's 2024 annual report, and investors are advised to make cautious decisions [8].
中红医疗(300981) - 2024 Q4 - 年度业绩预告